The Leukemia | search
Click here to view The Leukemia news from 60+ newspapers.
Bookmark or Share- Use of Ibrutinib in Early-Stage Chronic Lymphocytic LeukemiaIn a German phase III trial (CLL12), reported in the Journal of Clinical Oncology, Langerbeins et al found that ibrutinib prolonged the time to symptomatic disease in patients with early-stage chronic lymphocytic leukemia (CLL) vs placebo.However, no differences in overall survival were observed. Study Details. In the double-blind multicenter trial, 363 patients with asymptomatic, treatment ...
- Stratification and Treatment of Infants | SpringerLinkAcute lymphoblastic leukemia (ALL) in infants accounts for less than 5% of childhood ALL. Approximately 70–80% of the patients present with a very aggressive form of ALL with KMT2A gene rearrangement (KMT2A-r) and most of the published outcomes are dismal with
- Apollomics Announces Top-Line Results for Phase 3 Bridging Trial of ...Apollomics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies. The Company uses both targeted, immuno-oncology, and other approaches to address a range of cancer indications, such as acute myeloid leukemia, lung cancer, brain cancer, and other solid tumors.
- Apollomics Inc.: Apollomics Announces Top-line Results for Phase 3 ...The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with ...
- Apollomics Announces Top-line Results for Phase 3 Bridging Trial of ...The Phase 3 trial was a randomized, double-blinded bridging trial to evaluate the safety and efficacy of uproleselan administered with chemotherapy versus chemotherapy alone in patients with ...
More
